Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia
Open Access
- 1 January 2011
- journal article
- clinical trial
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 17 (7), CR376-CR380
- https://doi.org/10.12659/msm.881848
Abstract
Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection. We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (<1 cm). All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.This publication has 28 references indexed in Scilit:
- An outbreak of oropharyngeal tularaemia linked to natural spring waterJournal of Medical Microbiology, 2009
- Characterization and genotyping of strains of Francisella tularensis isolated in BulgariaJournal of Medical Microbiology, 2009
- Tularemia: History, Epidemiology, Pathogen Physiology, and Clinical ManifestationsAnnals of the New York Academy of Sciences, 2007
- Outbreak of tularaemia in Golcuk, Turkey in 2005: Report of 5 cases and an overview of the literature from TurkeyScandinavian Journal of Infectious Diseases, 2005
- Tularaemia outbreak in BulgariaScandinavian Journal of Infectious Diseases, 2004
- Fluoroquinolone Safety in Pediatric Patients: A Prospective, Multicenter, Comparative Cohort Study in FrancePEDIATRICS, 2003
- Tularemia Epidemic in Northwestern Spain: Clinical Description and Therapeutic ResponseClinical Infectious Diseases, 2001
- Streptomycin and Alternative Agents for the Treatment of Tularemia: Review of the LiteratureClinical Infectious Diseases, 1994
- In vitro susceptibility ofFrancisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Tularemia in children caused by Francisella tularensis biovar palaearcticaThe Pediatric Infectious Disease Journal, 1990